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a b s t r a c t
Exophiala oligosperma is an uncommon pathogen associated with human infections, predominantly in
immunocompromised hosts. Case reports of clinical infections related to E. oligosperma have been limited
to 6 prior publications, all of which have shown limited susceptibility to conventional antifungal
therapies, including amphotericin B, itraconazole, and fluconazole. We describe the first case of an
E. oligosperma induced soft-tissue infection successfully treated with a 3-month course of voriconazole
without persisting lesions.
& 2013 The Authors. Published by Elsevier B.V. on behalf of International Society for Human and Animal
Mycology.
1. Introduction
Exophiala is a genus of anamorphic fungi in the family
Herpotrichiellaceae [1]. The primary species causing human disease
is Exophiala dermatitidis. Isolates exhibit marked neurotropism and
are rare agents of severe, life-threatening cerebral phaeohyphomy-
cosis, primarily in Southeast Asia. The species is more commonly
recovered from respiratory, cutaneous, and subcutaneous sites, and
occasionally from other deep-seated infections. However, species
recently noted to be recovered from clinical samples, such as
Exophiala oligosperma and Exophiala xenobiotica, have also been
reported as agents of systemic phaeohyphomycosis [2]. Mycetoma
and phaeohyphomycosis are the most common infections asso-
ciated with this opportunistic pathogen. Although the majority of
these are non-life-threatening cutaneous infections, including sub-
cutaneous cystic lesions and soft-tissue abscesses, fatal systemic
infections have also been described. Case reports of clinical infec-
tions related to this organism have been limited to 6 prior
publications. We describe the first case of an E. oligosperma induced
soft-tissue infection successfully treated with a 3-month course of
voriconazole without persisting lesions requiring concomitant sur-
gical intervention.
2. Case
A 50-year-old Caucasian female presented in March of 2012
with progressively enlarging, painless, “rubbery-like” cutaneous
lesions on both of her legs over the past year. Although she noted
occasional thorn pricks from different plants while gardening, she
denied any prior major trauma to her legs. Occasionally, the
lesions spontaneously drained black, purulent fluid.
She has a 10-year history of systemic lupus erythematosis on
chronic immunosuppressive therapy with mycophenolate mofetil
500 mg daily and plaquenil 200 mg daily. She also has a history of
severe asthma and had been taking oral methylprednisolone
80 mg daily for years. Her vital signs were normal. She was
afebrile and hemodynamically stable. Her physical exam was
unremarkable except for the skin examination, which revealed
multiple, tender, raised, reddish-pink subcutaneous nodules with
some measuring 0.5–1 cm in diameter, while others were up to
3 cm in diameter, all grouped in the affected zone (Fig. 1). There
was no lymphadenopathy.
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A skin biopsy specimen obtained for histopathologic study and
microbiological cultures revealed suppurative granulomatous
inflammation in the deep dermis and hypodermis composed of
lymphocytes, epithelioid macrophages, multinucleated giant cells
and aggregations of neutrophils in the center of the granulomas
(Fig. 2). Periodic acid-Schiff (PAS) stain showed round-shaped
fungal structures (Fig. 3).
Fungal cultures were performed on Sabouraud chloramphenicol
agar and Sabouraud chloramphenicol cycloheximide agar (Bio-
Rad, Hercules, CA, U.S.A.), and incubated at 30 1C. After 10 days of
incubation, velvety colonies developed on all media, which were
olive-black with a blackish reverse. Microscopic examination of
these colonies revealed brown septate hyphae, annellidic conidio-
genous cells and oval conidia.
The isolate was subsequently referred to the Fungus Testing
Laboratory in the Department of Pathology at the University of
Texas Health Science Center at San Antonio (UTHSCSA DI 13-133),
for antifungal susceptibility testing and identification by combined
phenotypic characterization and DNA sequencing. Microscopic
features were consistent with an Exophiala sp. and lack of growth
at both 35 1C and 40 1C combined with a positive nitrate test
suggested a species other than E. dermatitidis. For DNA sequencing,
template DNA was prepared by subculturing the isolate onto PFA
and incubating at 30 1C for 24 h. Hyphal elements were scraped
from the agar surface, suspended in CPL-100 Buffer (VWR Inter-
national INC, Radnor, PA), lysed in a Bead Beater instrument, and
isolated manually by chloroform extraction method. Extracted
DNA was used for PCR amplification of ITS and D1/D2 regions as
described [30] with slight modification. PCR products were then
sequenced using the ITS1 and ITS4 primers as well as NL1 and NL4
primers [22] at the UTHSCSA Molecular Diagnostics Laboratory.
Sequences were assembled and analyzed using DNASTAR software
(DNASTAR, Inc., Madison, WI) and queried in Genbank using the
BLASTn algorithm at the NCBI site (www.ncbi.nlm.nih.gov).
Sequences were also compared to those available in the CBS-
KNAW Fungal Biodiversity Centre database (www.cbs.knaw.nl).
The ITS sequence of this isolate showed 100% identity to both
Exophiala jeanselmei (Genebank Accession no. AJ866273.1) and
E. oligosperma (Genebank Accession no. AB480204.1), and the D1/
D2 sequence showed 100% identity to E. oligosperma (CBS 265.49).
By barcode analysis, there was 100% match with E. oligosperma
(UTHSC 91-780) [31].
Minimum inhibitory concentrations (MICs, in μg/ml) were
performed via broth microdilution methods according to the CLSI
M38-A2 guidelines, (CLSI M38-A2) and were reported as follows:
amphotericin B 0.5 μg/ml, micafungin 0.25 μg/ml, posaconazo-
ler0.03 μg/ml, and voriconazole 0.125 μg/ml. The patient was
started on oral voriconazole 200 mg twice daily. A follow-up
assessment at 6 weeks showed interval reduction in the lesion size
and tenderness (Fig. 4). At 12 weeks, the lesions had completely
resolved and voriconazole was discontinued. She had no major side
effects to the antifungal regimen. A 6-month follow up visit did not
reveal any persistent lesions. Laboratory results, including complete
blood count, chemistry and liver panel were normal throughout the
treatment course.
3. Discussion
We searched the English-language literature published through
May 2013 in the PubMed database. Relevant studies were identi-
fied using various key word combinations including “Exophiala,
oligosperma, cutaneous” and “voriconazole.” No lower publication
date limit was set. Six published cases of E. oligosperma human
Fig. 1. Before voriconazole therapy – showing nodular and diffuse dermatitis.
Fig. 2. H&E stain demonstrating suppurative granulomatous inflammation in the
deep dermis and hypodermis composed of lymphocytes, epithelioid macrophages,
multinucleated giant cells and aggregations of neutrophils in the center of the
granulomas.
Fig. 3. Periodic acid-Schiff (PAS) stain of a punch biopsy from the proximal left hip
showing granulomatous dermatitis consistent with deep fungal infection.
Fig. 4. After voriconazole therapy – showing a decrease in size and resolution of
her fungal infection.
B.H. Rimawi et al. / Medical Mycology Case Reports 2 (2013) 144–147 145
infections were ascertained (Table 1). Of these six cases, four
showed susceptibility to voriconazole, with only one case describ-
ing successful clinical response to voriconazole, however, persis-
tent lesions were present that required surgical excision [24]
(Table 1).
Exophiala spp. are an emerging cause of skin and subcutaneous
tissue infections, particularly in immunocompromised hosts. They
have also been associated with systemic infections, including
prosthetic valve endocarditis, dialysis-associated peritonitis, and
disseminated infections [5–10]. These earlier reports originally
attributed to E. jeanselmei most likely represent other species
within the heterogeneous collection of yeast-like fungi [11].
Although the genus is often considered ubiquitous, several species
occupy specific ecological niches contributing to their pathogenic
potential. Exophiala spp. have been recovered from various climates,
including hot, humid and oligotrophic environments, such as
dishwashers, steam bath facilities, and bathrooms [12–14]. Other
species associated with systemic infections include E. dermatitidis,
E. phaeomuriformis, E. lecanii-corni, E. bergeri, E. spinifera,
E. mesophila, and E. attenuate [2].
Subcutaneous phaeohyphomycosis usually presents as an
asymptomatic, solitary nodule or abscess, usually found inciden-
tally on an extremity. The infection commences as a small nodule
that enlarges over months and may develop a pseudocapsule,
giving a cyst-like appearance, termed “phaeohyphomycotic cyst”
[18]. It has rarely been reported as multiple lesions [19]. In this
context, it is noteworthy that in our case there was a cluster of
inflammatory nodular lesions. The inoculation mechanism of the
fungus in our index case is unknown; however, she gives a
biologically plausible history of gardening with encounters of
being pricked by a variety of plant thorns. In other cases, a history
of prior trauma with splinters or other contaminated material
occurred months before the appearance of the lesions [20]. Given
the relatively nonspecific clinical features, subcutaneous phaeo-
hyphomycosis may be confused with other entities and, thus, a
high index of suspicion is required for early diagnosis.
The histopathologic picture is characterized by a granuloma-
tous infiltrate, sometimes encapsulated by fibrous tissue [18,20].
Diagnosis depends on visualization of hyphal or yeast-like
elements in tissue, and should be confirmed by isolation on cul-
ture and the morphological identification of the causal fungus.
Moreover, differentiation down to the species level is recom-
mended, as different species may have a different virulence or
resistance to antifungal therapy [21]. E. oligosperma has an olive-
black and velvety colony appearance, similar to that of other
Exophiala spp. In our case, identification of the causative agent
as E. oligosperma was achieved by a combination of phenotypic
characteristics and DNA sequence analysis.
There are no set Clinical and Laboratory Standards Institute
(CLSI) clinical breakpoints for antifungals against Exophiala
species. However, extrapolating from MICs for other pathogens
[3,4], we inferred activity for this isolate. As reported above,
susceptibility testing by the CLSI M38-A2 guidelines demonstrated
in vitro potency for various antifungals including amphotericin B
and the azoles voriconazole and posaconazole. However, the
treatment of choice for these rare infections has not yet been
established in clinical studies.
The scarce data illustrate the importance of further investiga-
tion of more appropriate therapies. Amphotericin B, alone or in
combination with flucytosine, or triazoles, such as voriconazole
and itraconazole, have been used, but without completely satis-
factory results [2]. Itraconazole has shown efficacy on some
occasions, but its use is limited by its variable gastrointestinal
absorption and alterations in cardiac conductivity [15]. Although
tested only in vitro, posaconazole has also demonstrated good
activity against clinical isolates of E. oligosperma [2,15]. In our
patient, voriconazole was chosen due to her history of gastro-
intestinal intolerance to many medications and inability to reliably
consume adequate dietary intake necessary for optimum absorp-
tion of posaconazole. Itraconazole was avoided due to her history
of atrial fibrillation. A minimum of 3–4 months of therapy with
voriconazole has been used [16], with up to 12 months in
immunocompromised hosts [17]. Surgical excision is considered
to be the treatment of choice when dealing with solitary, well-
delimited lesions [18,23].
Unlike the response to voriconazole described by Kan et al. [24] the
novelty in our index case is the complete resolution of symptoms
without residual lesions. Furthermore, this previous case also involved
Table 1
Cases of Exophiala oligosperma human infections with susceptibility to voriconazole (VCV)



















2003 62 Male Wegner's
granulomatosis,
olecranon bursitis




2006 3 Male CAFb, leukemia Yes Amphotericin B
itraconazole
fluconazole

















2011 57 Female None Not performed Terbinafine No Not
performed
6 Not applicable




Yes 0.125 3 Complete resolution
Our index
case
2013 50 Female SLEc Yes Voriconazole No 0.125 3 Not applicable
a μg/ml: micrograms per milliliter.
b CAF: catheter-associated fungemia.
c SLE: systemic lupus erythematosis.
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the use of itraconazole and surgical intervention. Our case illustrates
the efficacy of voriconazole as monotherapy without surgical inter-
vention other than what was needed for her initial biopsy. That said,
surgical intervention should be considered on a case-by-case basis.
Although the case described by Kan et al. [24] involved combination
antifungal therapies, clinical response was also seen at 3 months of
therapy. In comparison to the other 3 case reports that showed
susceptibility to voriconazole involving E. oligosperma cutaneous
infections, none of those cases used voriconazole therapy.
In summary, we describe the first case of an E. oligosperma
induced soft-tissue infection successfully treated with a 3-month
course of voriconazole with complete resolution of all lesions
noted with follow-up office visits. This may be likely secondary to
the fact that our patient's skin lesions were probably more super-
ficial and less extensive, when compared to the patients who
failed different antifungal therapies with the same fungus. Health-
care providers should consider E. oligosperma when a cutaneous
infection fails to respond to standard antimicrobials and broad,
conventional antifungal therapy such as amphotericin B, flucona-
zole, or itraconazole. Although clinical experience with voricona-
zole in cases of disseminated phaeohyphomycosis caused by
E. oligosperma is still scarce, voriconazole has shown the most
promising results to date.
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